Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 15 Years to 60 Years; no BMI minimum stated; conditions: Diabetes Mellitus, Type 1
- Interventions
- Liraglutide
- Conditions
- Diabetes Mellitus, Type 1
- Phase and size
- Phase 3 · 35 participants
- Dates
- Start 2022-07-01
Primary completion 2023-02-28 - Sponsor
- David Sanchez Garcia (Other gov)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.Baseline and 6 months
02Eligibility
Who can take part
Inclusion Criteria: * Age from 15 to 60 years * Patients diagnosed with Type 1 Diabetes Mellitus. * Diabetes duration more than 1 year. * Both genders. * C - peptide less than 0.3 nmol/L Exclusion Criteria: * Patients with type 2 diabetes mellitus, LADA (latent autoimmune diabetes in adults), MODY (maturity-onset diabetes of youth), or other types of diabetes other than type 1 diabetes mellitus. * Pregnant patients or desire to become pregnant in the next 6 months. * Family history of medullary thyroid cancer or multiple endocrine neoplasia 2 * History of pancreatitis * Familial hypercholesterolemia * Use of adjunctive treatment to insulin (SGLT-2 \[sodium-glucose cotransporter-2\] inhibitor, Pramlintide, metformin) * Start of treatment with statins, ezetimibe or PSCK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, amlodipine, metoprolol in the last 6 months before the study. * Bariatric surgery * Use of medications (immunosuppressants, calcineurin inhibitors, mTOR (mammilian target of rapamycin) inhibitors, corticosteroids, aspirin, or anticoagulants) * Metabolic abnormalities (inborn errors of cholesterol storage metabolism, glycogen storage, abetalipoproteinemia, Reye's disease, LCAT (lecithin-cholesterol acyltransferase) deficiency)
03Change log
Registry changes
No changes recorded since the trial was added.